Drugs / GW5282
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07496229 | Apr 2026 → Sep 2029 expected | T-cell non-Hodgkin lymphoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07328217 | Jan 2026 → Dec 2028 expected | cancer | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW5282 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07496229 ↗ |
| Route | Oral | “administered orally” NCT07328217 ↗ |